Skip to content

Clinical Study on the Efficacy of Dragon-Tiger Battle Acupuncture Combined with Jiaji Point Injection for Refractory Postherpetic Neuralgia

Clinical Study on the Efficacy of Dragon-Tiger Battle Acupuncture Combined with Jiaji Point Injection for Refractory Postherpetic Neuralgia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001319
Enrollment
Unknown
Registered
2025-07-01
Start date
2024-06-26
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory post-herpetic neuralgia

Interventions

Western medicine+acupuncture group 1:According to the main pain site of PHN, the corresponding acupoints were selected and the dragon-tiger fighting needling method was used. The acupoint injection wa
Western medicine group:Only combined medication, no other special intervention.
Western medicine+acupuncture group 2:Acupuncture was performed on the corresponding Jiaji acupoints in the herpes skin lesion and pain area, and the Jiaji acupoints corresponding to the skin lesion si

Sponsors

Chengdu Third People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: According to the Expert Consensus of Diagnosis and Treatment of Postherpetic Neuralgia in China (2016) and the Expert Consensus of Diagnosis and Treatment of Herpes Zoster in China (2022) the diagnostic criteria of PHN are as follows: (1) There is a clear history of herpes zoster and pain remains after the characteristic skin lesions subside and lasts for one month or more.

Exclusion criteria

Exclusion criteria: (1) lactating or pregnant women; (2) Patients with malignant tumor immune mental or serious diseases such as heart liver kidney and brain or abnormal coagulation function; (3) Those who have received other relevant treatments; (4) Patients with other serious complications of herpes zoster or other skin diseases; (5) Refusing to sign the informed consent; (6) Participated in other clinical studies in the past six months and the results of this study may be evaluated as disruptor by the researchers or they plan to participate in other clinical researchers during their participation in this study; (Note: Patients who meet any one of the above items will be excluded. )

Design outcomes

Primary

MeasureTime frame
visualanaloguescal;

Secondary

MeasureTime frame
Anxiety state score;Pittsburgh sleep quality index score;Infrared thermal imaging;Depressive state score;

Countries

China

Contacts

Public ContactYu Wang

Chengdu Third People's Hospital

29733197@qq.com+86 138 8092 4834

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026